NVO logo

NVO
Novo Nordisk A/S

31,042
Mkt Cap
$129.78B
Volume
16.91M
52W High
$81.44
52W Low
$35.12
PE Ratio
11.09
NVO Fundamentals
Price
$40.94
Prev Close
$38.52
Open
$40.07
50D MA
$39.53
Beta
0.91
Avg. Volume
19.26M
EPS (Annual)
$3.49
P/B
5.61
Rev/Employee
$679,358.45
$242,651.58
Loading...
Loading...
News
all
press releases
Novo Nordisk A/S (NYSE:NVO) Trading Up 5.9% - Still a Buy?
Novo Nordisk A/S (NYSE:NVO) Trading 5.9% Higher - Should You Buy...
MarketBeat·45m ago
News Placeholder
More News
News Placeholder
Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children
Novo Nordisk shares are up on Friday after reporting oral semaglutide trial results in children aged 10-17 years old with type 2 diabetes.read more...
Benzinga·4h ago
News Placeholder
Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect?
INCY heads into Q1 earnings with a $1.23 billion revenue view, driven by Jakafi, Opzelura, rising royalties and multiple new launches contributing to revenues.
Zacks·5h ago
News Placeholder
OLD National Bancorp IN Buys 38,631 Shares of Novo Nordisk A/S $NVO
OLD National Bancorp IN raised its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 317.8% during the 4th quarter, according to the company in its most recent 13F filing with the...
MarketBeat·7h ago
News Placeholder
HIMS Stock Gets Pre-Market Boost – JPMorgan Initiation Flags ‘Turning Point’ With Novo Nordisk
JPMorgan initiated coverage of Hims & Hers with an ‘Overweight’ rating and a price target of $35, according to The Fly.
Stocktwits·8h ago
News Placeholder
Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Novo Nordisk (NVO) closed at $38.52, indicating a -1.61% shift from the previous trading day.
Zacks·20h ago
News Placeholder
Hims stock price reacts strongly to crucial FDA review
Hims & Hers (HIMS) has caught a powerful new tailwind, and the market is treating peptides as more than a short-lived headline. The immediate catalyst was the FDA's decision to hold a July 23-24...
TheStreet.com·24h ago
News Placeholder
Altimmune Catalysts: 2026 Data Readouts and Financing Risks
ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.
Zacks·1d ago
News Placeholder
ALT Stock: What Pemvidutide Means for MASH, AUD and ALD
Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.
Zacks·1d ago
News Placeholder
Is Altimmune a Buy Before Phase III MASH Starts in 2026?
ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its valuation-or risk setbacks.
Zacks·1d ago
<
1
2
...
>

Latest NVO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.